Navigation Links
Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
Date:6/4/2011

(pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties. The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amylin's most recently filed SEC documents, including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
2. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
3. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
6. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
7. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
10. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
11. Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... Global,s shared e-clinical service desk expands support to another ... leading ... Inc. (Nasdaq: TEAM ), a worldwide provider of information ... its subsidiary, TechTeam Global nv/sa, has been selected by,sanofi-aventis recherche ...
... MA--Researchers from Boston University School of Medicine have developed ... cancer. The model combines a specific gene expression ... These findings currently appear on-line in the journal ... leading cause of cancer death in the United States ...
... CHAPEL HILL, N.C., April 1, 2008 Faced ... forces are,having a challenging time serving the hospital ... to shrink, sales reps for the,pharma industry are ... win a place on formularies, according to research ...
... with Guaranteed Withdrawal Benefit, Turns Assets from Retirement ... ... Fortune 1000 Employees, NEW YORK, April 1, 2008 ... variable annuities,today launched a new variable annuity -- Crossings(SM): My ...
... Many top-selling drugs used to treat cancer and ... which are found in nature but historically difficult for ... For the first time, scientists at UC Irvine have ... easier for chemists to manipulate them into new drugs. ...
... 2008) Many patients who come to the ... are already taking 75mg of clopidogrel daily to ... 600-mg reloading dose of clopidogrel significantly improves clinical ... in patients with acute coronary syndromes (ACS), according ...
Cached Medicine News:Health News:TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement 2Health News:TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement 3Health News:Researchers develop new method to test for lung cancer 2Health News:Effectively Influencing the Hospital Marketplace to Win a Place on Formularies 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 3Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 4Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 6Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 7Health News:Scientists solve mystery of polyketide drug formation 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2
For the quantitative determination of uric acid in serum....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: